HK1038194B - Polyol-ifn-beta conjugates - Google Patents

Description

Polyol interferon β conjugates

Cross Reference to Related Applications

Priority of U.S. provisional application No. 60/083,339 is claimed in 35 u.s.c. § 119(e), the entire content of which is incorporated herein by reference.

Technical Field

The present invention relates to polyol-IFN- β conjugates in which the polyol unit and Cys are¹⁷And (4) covalently bonding. Another object of the invention is the process of site-specific generation thereof and its use in the treatment, prognosis or diagnosis of bacterial infections, viral infections, autoimmune diseases and inflammatory diseases. The invention also relates to methods for the stepwise conjugation of two or more PEG molecules to a polypeptide.

Background

Human fibroblast interferon (IFN- β) has antiviral activity and also stimulates natural killer cells against tumorigenic cells it is a viral and double-stranded RNA induced polypeptide of about 20,000Da Derynk et al (Nature of nature,285: 542-547, 1980) the complete amino acid sequence of the protein was deduced from the nucleotide sequence of the fibroblast gene cloned by recombinant DNA techniques. It is 166 amino acids long.

Shepard et al (Nature of nature,294: 536-565, 1981) describe that the base mutation at position 842 abolishes its antiviral activity (position 141Cys → Tyr), and that variant clones with a deletion of nucleotides 1119-1121.

Mark et al (Proc.Natl.Acad.Sci.U.S.A.，81(18)：5662-5666，1984) An artificial mutation was inserted by replacing the 469(T) base with (A), resulting in an amino acid transition from Cys → Ser at position 17 IFN- β was reported to be as active as "native" IFN- β and to remain stable during long term storage (-70 ℃).

Covalent attachment of the hydrophilic polymer polyethylene glycol (PEG), also known as polyethylene oxide, to molecules is an important application in biotechnology and medicine. PEG in its most common form is a linear polymer with hydroxyl groups at each end:

HO-CH₂-CH₂O(CH₂CH₂O)_nCH₂CH₂-OH

this molecular formula can be simply represented by HO-PEG-OH, where-PEG-represents a polymer backbone without terminal groups:

"-PEG-" means "-CH₂CH₂O(CH₂CH₂O)_nCH₂CH₂-

PEG is commonly used as methoxy-PEG-OH, where one terminus is a relatively inert methoxy group and the other terminus is a hydroxyl group to be chemically modified.

CH₃O-(CH₂CH₂O)_n-CH₂CH₂-OH

Branched PEG is also commonly used. Branched PEG may be represented by R (-PEG-OH)_mWhere R represents, for example, a central core molecule of neopentyl glycol or glycerol and m represents the number of branched arms. The number of branching arms (m) can vary from three to 100 or more. The hydroxyl groups are chemically modified.

Other branched forms, as described in PCT patent application WO 96/21469, have a single end that is chemically modified. This PEG type can be expressed as (CH)₃O-PEG-)_pR-X, wherein p is equal to 2 or 3, R represents a central core of, for example, lysine or glycerol, and X represents a functional group such as a carboxyl group capable of chemical activation. While another branched form, the "pendant PEG" has a reactive group such as a carboxyl group (which is predominantly on the PEG backbone rather than at the end of the PEG chain).

In addition to these forms of PEG, polymers can also be prepared with weak or degradable bonds in the backbone. For example, Harris has shown in us patent application 06/026,716 that PEG can be prepared using ester linkages in the backbone of a polymer that can undergo hydrolysis. This hydrolysis (reaction) results in the polymer being cut into smaller molecular weight fragments, according to the reaction scheme:

according to the invention, the term polyethylene glycol or PEG is meant to include all the above derivatives.

Co-polymers of ethylene oxide and propylene oxide are closely related in their chemistry to PEG and they can be used to replace many applications of PEG. They have the following general formula:

HO-CH₂CHRO(CH₂CHRO)_nCH₂CHR-OH

wherein R is H or CH₃。

PEG is a useful polymer with properties of high water solubility and high solubility in many organic solvents. PEG is neither toxic nor immunogenic. When PEG and water-insoluble compounds are chemically combined (PEGylated), the resulting conjugates are generally water-soluble and soluble in many organic solvents.

PEG-protein conjugates are now used in protein replacement therapy and other therapeutic applications. For example, PEGylated Adenosine Deaminase (ADAGEN)^®) Will be used for the treatment of Severe Combined Immunodeficiency Disease (SCIDS), PEGylated L-asparaginase (ONCAPSPAR)^®) Will be used in the treatment of Acute Lymphoblastic Leukemia (ALL), while pegylated interferon- α (INTRON (R) A) is undergoing a three phase trial for the treatment of hepatitis CAnd (6) testing.

For a review of PEG protein conjugates with clinical efficacy, we can see n.l. burnham,Am.J.Hosp.Pharm.，15：210-218，1994。

conjugation of PEG to reactive groups found on proteins is typically accomplished using electrophilically activated PEG derivatives.conjugation of PEG to lysine residues and α -and epsilon-amino groups found at the N-terminus yields conjugates that constitute a product mixture.

Typically, these conjugates include conjugates in which the number of PEG molecules bound per protein molecule varies from 0 to the number of amino groups in the protein. For protein molecules that have been modified individually, PEG units can be attached at a number of different amine sites.

For example, Katre et al, in U.S. Pat. No. 4,766,106 and U.S. Pat. No. 4,917,888, describe PEGylation of IFN- β and IL-2 with an excess of methoxy-polyethylene glycol N-succinimidyl glutarate and methoxy-polyethylene glycol N-succinimidyl succinate both proteins are produced in microbial host cells, which allow for the specific mutation of the free cysteine site to serine^®Wherein Cys is¹⁷Is replaced by serine. In addition, the lack of glycosylation reduces its solubility in aqueous solutions. Non-specific pegylation results in increased solubility, but the main problem is reduced levels of activity and yield.

European patent application EP 593868 (entitled PEG-interferon conjugates), describes the preparation of PEG-IFN- α, however, the PEGylation reaction is not site-specific and therefore a mixture of positional isomers of PEG-IFN α conjugates is obtained (see also Monkarsh et al,ACS.Symp.Ser.，680：207-216，1997)。

kinstler et al in European patent application EP 675201 demonstrated the selective modification of the N-terminal residue of Megakaryocyte Growth and Development Factor (MGDF) with mPEG-propionaldehyde this allows for batch-to-batch reproducible PEGylation and pharmacokinetics Gilbert et al in U.S. Pat. No. 5,711,944 demonstrated PEGylation that produced IFN- α with optimal levels of activity, in this case laborious purification steps were required to obtain the optimal conjugate.

Most cytokines, as well as other proteins, do not have specific PEG binding sites and, in addition to the examples mentioned above, it is likely that some of the isoforms produced by the pegylation reaction are partially or completely inactive, resulting in loss of activity of the final mixture.

Site-specific mono-pegylation is therefore an ideal target in the preparation of these protein conjugates.

Woghiren et al inBiocon jugate Chem.,4(5): thiol-selective PEG derivatives were synthesized for such site-specific PEGylation in 314-318, 1993. The stable thiol-protected PEG derivative is shown to be specifically conjugated as a disulfide-p-pyridine reactive group to the free cysteine of the protein papain. The newly formed disulfide bond of papain and the PEG ester bond can be cleaved under mild degradation conditions to regenerate the native protein.

The citation of any document herein is not an admission that such document is prior art or is prior art with respect to any patentable material of the present application. Any statement as to the contents and timing of any document is based on the information available to the applicant at the time of filing and is not an admission as to the correctness of the statement.

Disclosure of Invention

Provided herein are polyol-IFN- β conjugates, particularly PEG-IFN- β conjugates, in which the polyol unit is conjugated to Cys¹⁷By combining a thiol-reactive polyol agent with Cys in IFN- β¹⁷The goal is to achieve increased solubility at moderate pH, increased stability (reduced aggregation), reduced immunogenicity, and no loss of activity compared to "native" IFN- β.

The invention also provides a method for continuous stepwise conjugation of PEG molecules to polypeptides.

Drawings

FIG. 1 shows a Capillary Electrophoresis (CE) image before purification of PEG-IFN- β.

FIGS. 2A-2C show the purification of PEG-IFN- β conjugate by size exclusion chromatography (Superose 12). FIG. 2A-first pass, FIG. 2B-second pass, and FIG. 2C-third pass.

FIG. 3 shows SDS-PAGE chromatography of purified PEG-IFN- β conjugate from the third pass, lanes 1 and 4 are protein molecular weight standards, lane 2 is "native" IFN- β, and lane 3 is a PEG-IFN- β conjugate.

FIG. 4 reports purified PEG-IFN- β conjugates (where IFN was mPEG-OPSS)_5kPegylation) of the sample.

FIG. 5 reports MALDI MS chromatography of purified PEG-IFN- β conjugate.

FIG. 6 shows a "comparison of the antiviral activity of the natural IFN- β and PEG-IFN- β conjugates.A sample of IFN- β at the indicated concentration was incubated with WISH cells for 24 hours before challenge with the cytopathic dose of vesicular stomatitis virus.the cytopathic effect was measured by MTT method after an additional 48 hours.

FIG. 7 shows the binding of IFN- β and PEG-IFN in Daudi cells.

FIG. 8 shows the pharmacokinetics of IFN- β and PEG-IFN in mice after intravenous administration the dashed lines indicate the LOQ determination for each standard curve.

FIG. 9 shows the pharmacokinetics of IFN- β and PEG-IFN in mice after subcutaneous administration.

Detailed Description

The invention is based on polyol molecules, in particular PEG molecules, with Cys of human IFN- β¹⁷The unexpected discovery that residue binding increased (or at least remained without resulting in a decrease) the biological activity of IFN- β over that of natural human interferon- β¹⁷Residue-bound IFN- β not only displays the same or increased IFN-β, and the polyol-IFN- β conjugate also provides desirable properties conferred by the polyol molecule, such as increased solubility.

"IFN- β", as used herein, refers to human fibroblast interferon, as obtained by isolation from biological fluids, or from prokaryotic or eukaryotic host cells using recombinant DNA techniques, and salts, functional derivatives, precursors and active fragments thereof, defined as containing a cysteine residue at position 17 in naturally occurring form.

The polyol molecule in the polyol-IFN- β conjugate according to the invention may be any water-soluble mono-or bifunctional poly (alkylene oxide) having linear or branched chains typically the polyol is poly (ethylene glycol) (PEG).

The term "PEG molecule" as used herein refers to molecules including, but not limited to, linear or branched PEG, methoxy PEG, hydrolyzable or enzymatically cleavable PEG, pendant PEG, dendrimer PEG, copolymers of PEG and one or more polyols, and PEG and PLGA (poly (lactic/glycolic acid)) copolymers.

The definition "salt" as used herein refers both to salts of carboxyl groups and to salts of amino functions of compounds obtainable by known methods. Salts of carboxyl groups include inorganic salts such as sodium, potassium, calcium salts and salts with organic bases formed, for example, with amines such as triethanolamine, arginine or lysine. Salts of amino groups include salts with inorganic acids, such as hydrochloric acid, and salts with organic acids, such as acetic acid.

The definition "functional derivative" as used herein refers to a derivative which can be prepared according to known methods from functional groups present in the side chains or in the terminal N-C-group of amino acid molecules and which is included in the present invention when it is pharmaceutically acceptable, i.e. when it does not destroy the activity of the protein or confer toxicity on the pharmaceutical compositions containing them. Such derivatives comprise esters or fatty acids of the carboxyl group and N-acyl derivatives of the free amino group or O-acyl derivatives of the free hydroxyl group and are formed by acyl groups, such as chain acyl-or aroyl-groups.

A "precursor" is a compound that is converted to IFN- β in the human or animal body.

By "active fragment" of a protein, the invention refers to any fragment or precursor of the compound itself polypeptide chain, alone or in combination with a related molecule or residue, such as a sucrose or phosphate residue, or a polymer of polypeptide molecules, associated therewith, when such fragment or precursor exhibits the same IFN- β activity as the drug.

According to one embodiment of the invention, IFN- β and a PEGylating agent are reacted in a suitable solvent, and the desired conjugate is isolated and purified, for example, by performing one or more chromatographic methods.

"chromatographic process" refers to any process for separating components of a mixture by linking them to a support (stationary phase) through which a solvent (mobile phase) flows. The separation principle of chromatography is based on the different physical properties of the stationary and mobile phases.

Some specific types well known in the chromatography literature include: liquid phase, high performance liquid phase, ion exchange, absorption, affinity, separation, hydrophobic, reverse phase, gel filtration, ultrafiltration or thin layer chromatography.

As used herein, "thiol-reactive pegylating agent" refers to any PEG derivative that is capable of reacting with the thiol group of a cysteine residue. It may be PEG containing, for example, disulfide para-pyridine, vinyl sulfone, maleimide, iodoacetamide, and other functional groups. According to a preferred embodiment of the invention, the thiol-reactive PEGylating agent is a dithiopyridine (OPSS) derivative of PEG.

The PEGylating agent is used in its mono-methoxylated form, in which only one end can be coupled, or in a bifunctional form, in which both ends can be coupled, for example in the form of two IFN- β covalently linked to one PEG molecule to form a conjugate, the molecular weight is preferably between 500 and 100,000.

A typical reaction scheme for the preparation of the conjugates of the invention is as follows:

the mPEG-OPSS derivatives are highly selective for free sulfhydryl groups and react rapidly under the acidic pH conditions at which IFN- β is stable, high selectivity can be demonstrated from a reduction in coupling with IFN- β and the native form of PEG.

The disulfide bond created between the protein and the PEG molecule has been shown to be stable in circulation, but it is reduced upon entry into the cellular environment. It is therefore desirable that the conjugate does not enter the cell and remains stable in the circulation until cleared.

It is noted that the above reaction is site-specific, as the other two Cys residues at positions 31 and 141 in the naturally occurring form of human IFN- β do not react with the thiol-reactive pegylation agent due to the formation of disulfide bridges.

The invention also features a method for the sequential, stepwise conjugation of two or more PEG molecules to a polypeptide. This method is based on the recognition that low molecular weight activated PEG reacts more completely with steric hindrance reactive sites on proteins than high molecular weight activated PEG. PEG modification of expensive therapeutic proteins in order for PEG conjugates to be practical to produce, must be cost effective. In addition, in order to reduce glomerular filtration and optimize the pharmacological properties of the PEG-protein conjugate, the conjugate must have an effective size comparable to a protein with a molecular weight of 70 kDa. This means that for site-specific modification to which one PEG is to be attached, it is preferred to attach one PEG derivative having a molecular weight above 20 kDa. If the modification sites are sterically crowded, reactive groups on large PEG molecules may be difficult to reach the modification sites and thus will result in low yields. Preferred methods for PEGylating polypeptides according to the invention improve the yield of site-specific PEGylation by first incorporating small heterobifunctional or homobifunctional PEG molecules that can react with sterically crowded sites due to their relatively small size. Subsequent conjugation of large molecular weight PEG derivatives with the small PEG yields high yields of the desired PEGylated protein.

According to the present invention, a method for the sequential stepwise attachment of two or more PEG molecules to a polypeptide comprises first attaching a low molecular weight hetero-bifunctional or homo-bifunctional PEG molecule to the polypeptide and then attaching a mono-functional or bifunctional PEG molecule to the end of the low molecular weight PEG molecule attached to the polypeptide, after the sequential stepwise attachment of two or more PEG molecules to the polypeptide, wherein the polypeptide is preferably IFN- β and wherein Cys17 at the sterically crowded site is a preferred site for PEG attachment, the PEG-polypeptide conjugate can be purified using one or more purification techniques such as ion exchange chromatography, size exclusion chromatography, hydrophobic reaction chromatography, affinity chromatography and reverse phase chromatography.

The low molecular weight PEG molecules have the molecular formula:

W-CH₂CH₂O(CH₂CH₂O)_nCH₂CH₂-X，

wherein W and X are groups that react with amine, thiol, carboxyl or hydroxyl functional groups, respectively, to bind low molecular weight PEG molecules to the polypeptide. W and X are preferably independently selected from the group consisting of dithio-p-pyridine, maleimide, vinyl sulfone, iodoacetamide, amine, thiol, carboxyl, active ester, benzotriazole carbonate, p-nitrophenyl carbonate, isocyanate, and biotin. The low molecular weight PEG molecules preferably have a molecular weight in the range of about 100 to 5,000 daltons.

The monofunctional or bifunctional PEG molecule used to bind to the free end of the low molecular weight PEG conjugated to the polypeptide preferably has a molecular weight ranging from about 100 daltons to 200kDa, and is preferably methoxy PEG, branched PEG, hydrolysable or enzymatically cleavable PEG, pendant PEG, or dendrimer PEG. However, functional or bifunctional PEG also has the formula:

Y-CH₂CH₂O(CH₂CH₂O)MCH₂CH₂-Z，

wherein Y is reactive with the free end group of a low molecular weight PEG molecule bound to the polypeptide and Z is-OCH₃Or a group that reacts therewith to form a bifunctional conjugate.

PEG-polypeptide conjugates produced by a process in which two or more PEG molecules are successively conjugated stepwise to a polypeptide, wherein the polypeptide is effective as an active ingredient, can be used to produce a medical or pharmaceutical composition for the treatment of a disease or disorder.

It is another object of the invention to provide the conjugates in a sufficiently purified form to render them suitable for use as pharmaceutical compositions, as active ingredients in the treatment, diagnosis or prognosis of bacterial and viral infections and autoimmune, inflammatory diseases and tumours. Such a pharmaceutical composition represents a further object of the present invention.

Non-limiting examples of such diseases include: septic shock, AIDS, rheumatoid arthritis, lupus erythematosus and multiple sclerosis.

Other embodiments and advantages of the invention will be demonstrated in the following description.

One embodiment of the invention is to administer a pharmacologically active amount of a conjugate of the invention to a person threatened by the occurrence of one of the diseases reported above or to a person already showing such a pathological state.

Any route of administration compatible with the active principle can be used. Parenteral administration, such as subcutaneous, intramuscular or intravenous injection, is preferred. The dose of active ingredient to be administered is determined on the basis of the medical prescription with reference to the age, weight and individual response of the patient.

For an average body weight of 75 kg, the dose may be between 10 micrograms and 1mg per day, whereas a preferred daily dose is between 20 micrograms and 200 micrograms.

Pharmaceutical compositions for parenteral administration can be prepared in injectable form containing the active principle and a suitable carrier. Carriers for parenteral administration are well known in the art and include, for example, water, saline solution, Ringer's solution and/or glucose. The carrier can contain small amounts of excipients to maintain stability and isotonicity of the pharmaceutical preparation. Solution preparation can be carried out in accordance with conventional formats.

The present invention has been described in terms of specific embodiments, but the description includes all variations and alternatives that may be suggested by those skilled in the art, not exceeding the intent and intent of the claims.

The invention will now be illustrated by the following examples, which are not intended to limit the invention in any way.

Example 1 preparation of PEG-IFN- β conjugate

mPEG for IFN- β_5kModification of OPSS

Recombinant human IFN- β stable at pH3.6 at a concentration of 0.37mg/ml in 50mM sodium acetate buffer was used for PEG-IFN- β preparation about 1.0ml of 6M urea at a concentration of 0.37mg/ml (0.74mg, 3.7X 1^-8Mol) was added to 2ml of IFN- β, mPEG was added as the remainder of 50M to 1M IFN- β mol_5K-OPSS, both reacted in a polypropylene vial at 37 ℃ for 2 hours or at 50 ℃ for 1 hour, prior to any purification step, the reaction mixture is analyzed by Capillary Electrophoresis (CE) to determine the extent of PEG-IFN- β conjugate formation by pegylation reaction (fig. 1), the typical yield of the reaction is 50% PEG-IFN- β, the reaction product is filtered from the reaction mixture using a 0.22mM syringe filter, the filtrate is then applied to a size exclusion chromatography column (either Superose12 or suoedex 75, Pharmacia), elution is performed with 50mM sodium phosphate, 150mM NaCl, ph7.5 buffer, fig. 2A shows the elution pattern of the PEG-IFN- β conjugate purified on the Superose12 size exclusion chromatography column, peaks are collected and analyzed by SDS-PAGE (fig. 3), the fractions containing the PEG-IFN- β are pooled together, the fractions are concentrated on a new "natural" IFN-34 peak (fig. 3) and the purification is repeated by the same capillary electrophoresis process (maldi.e. 25-595).

mPEG for IFN- β_30KModification of OPSS

It is provided at 0.36mg/ml in 50mM sodium acetate buffer, pH3.6StabilizedRecombinant human IFN- β dissolved in 3ml of deionized H₂About 36mg mPEG of O_30KOPSS was added to a concentration of 0.36mg/ml (1.08mg, 4.9X 10)^-8Molal) of 3ml of IFN- β, the two were allowed to react in a polypropylene tube at 50 ℃ for 2 hours, the degree of modification of the reaction mixture was analyzed by capillary electrophoresis, the usual yield of the reaction was less than 30%, and the solution was then applied to a size exclusion chromatography column (Superose12, Pharmacia) and washed with 50mM sodium phosphate, 150mM NaCl, pH7.0 bufferAnd (4) removing. Peaks were collected and the contents analyzed by SDS-PAGE.

Example 2 biological Activity of PEG-IFN- β conjugates

To evaluate the effect of pegylation on the antiviral activity of human recombinant IFN- β, human WISH amniotic cells were pre-cultured with freshly prepared IFN- β (same batch used for pegylation) or a PEG-IFN- β conjugate.According to the method based on Novick et al,journal of immunology129: 2244-2247(1982) as tested using the WISH-VSV cytopathic assay to determine IFN- β -mediated antiviral activity the following materials were used in the WISH assay:

WISH cells (ATCC CCL 25)

The vesicular stomatitis virus stock (ATCC V-520-

IFN- β, human recombinant, Interpharm Laboratories LTD (32,075-species, Batch #205035), 82X 10⁶IU/ml, specific activity: 222X 10⁶IU/mg

PEG-IFN- β conjugate prepared as in example 1, stored in PBS, pH7.4

WISH growth medium (MEM high glucose and Earls salts + 10% FBS + 1.0% L-Glutamine + penicillin/streptomycin (100U/ml, 100. mu.g/ml))

WISH test medium (MEM high glucose and Earls salt + 5% FBS + 1.0% L-Glutamine + penicillin/streptomycin (100U/ml, 100. mu.g/ml))

5mg/ml MTT in PBS, stored at-70 ℃.

The protocol for the WISH test is as follows:

IFN- β samples were diluted to the starting concentration in the 2XWISH assay medium.

The IFN- β samples from the WISH assay medium at 3-fold dilutions were placed in flat bottom 96-well plates so that each well contained 50 microliters of diluted IFN- β sample (some control wells contained only 50 microliters of WISH test medium)

WISH cells in the logarithmic growth phase were collected with a trypsin/EDTA solution, washed with WISH assay medium, and brought to a final concentration of 0.8X 10⁶Cells/ml.

50 microliters of WISH cell suspension (4X 10) was added⁴Cells/well) was added to each well the final concentration of IFN- β contacted with the cells was 1X.

At 5% CO₂After 24 hours incubation in a humidified incubator, 50 microliters of a 1: 10 diluted (in WISH test medium) VSV stock (at a dose intended to lyse 100% WISH cells over 48 hours) was added to all wells except the virus-free control wells (these were added only to an equal volume of test medium).

After an additional 48 hours, 25 microliters of MTT solution was added to all wells, and the plates were then incubated in the incubator for an additional 2 hours.

The contents of the wells were removed by inverting the plate and 200 microliters of 100% ethanol was added to the wells.

After 1 hour, plates were read at 595nm using the Soft max Pro software package and the Spectramax spectrophotometer System (Molecular Devices).

TABLE 1 antiviral Activity of PEGylated and mock-PEGylated IFN- β samples

IFN- β sample*	EC50 **
		PEG-IFN- β conjugates	3.9+/-0.7pg/ml
IFN-β	16.4+/-1.0pg/ml

^*Stock concentration of IFN- β in samples determined by amino acid analysis

^**EC determined with the software program Microcal Origin 4.1₅₀(+/-S.D.)

As shown in figure 6 and table 1 above, PEG-IFN- β conjugate maintained a level of antiviral activity higher than that of the freshly prepared IFN- β parent batch.

The PEG-IFN- β conjugate was observed to have approximately 4-fold greater biological activity than freshly prepared IFN- β, which may also be the result of greater stability of the PEG-IFN- β conjugate after addition of WISH cell assay medium compared to "native" IFN- β.

Example 3: in vitro assay of the relative Activity of PEG-IFN samples

The relative biological activity of PEG [30kD ] -IFN- β and PEG [ 2X 20kD ] -IFN- β was determined by the WISH assay using the standard protocol described in example 2 (Table 2). three independent assays were performed by three different people at different times.

TABLE 2 relative antiviral Activity of PEG-IFN- β

	Relative interferon activity*(from three studies)
					Sample (I)	Test 1	Test 2	Test 3	Average (S.D.)
PEG[30kD]-IFN-β	3.2X higher	3.1X higher	1.8X higher	3.0X (0.78) higher
					PEG[2×20kD]-IFN-β	4.2X higher	1.3X higher	0.85X higher	2.1X (1.8) higher

^*EC50 dose was compared to the standard IFN- β contained in each experiment

^**The comparison was based on 330 micrograms/ml IFN- β concentration the PEG [30kD ] was determined with AAA]IFN- β (5.41. mu.g/ml) and PEG [ 2X 20kD]Stock concentration of IFN- β (6.86. mu.g/ml).

At a fixed amount¹²⁵Evaluation of PEG-IFN- β binding to its receptor on cells in the Presence of I-IFN- α 2a Chloramine T method of use¹²⁵I radiolabeling IFN- α 2a the reaction was passed through a Sephadex G25 column and combined with a protein containing fractions (Pharmacia) to obtain a conjugate¹²⁵I bound IFN α 2a free iodine was removed IFN- α 2a ELISA assay (Biosource, USA) was used for quantification¹²⁵I-IFN- α 2a and the specific activity was determined.The logarithmic phase of Daudi cells were collected and 2X 10 cells were assayed in the presence of PEG-IFN- β or IFN- α 2a diluted in RPMI 1640 assay buffer containing 2% fetal bovine serum and 0.1% sodium azide at different concentrations⁶Cells and 0.5nM¹²⁵I-IFN- α 2a was cultured for 3 hours at room temperature at the end of the culture, the cells were centrifuged through a layer of phthalate oil and the cell-bound radioactivity was counted using a gamma counter, in addition, PEG [30kD ]]IFN- β and PEG [ 2X 20kD]IFN- β binds to the receptor with very similar or close binding activity as shown in FIG. 7.

In addition, relative activity was determined in Daudi cell (human B-cell lymphoma) antiproliferative assays (table 3). All IFNs were prepared at a 2X concentration of 200 ng/ml. The sample was diluted 3 times the length of the plate to a final volume of 100 microliters. Will be 1 × 10⁵Cells/well (100. mu.l) were added to each well and CO-cultured in a CO2 humidified incubator at 37 ℃ for 72 hours. After 48 hours, tritium (E) (1. mu. Ci/well in 20. mu.l³H) The results shown in Table 3 indicate that no detectable loss of IFN was observed from PEGylation in fact, the activity was found to be slightly higher than that of free IFN- β. this may be due to the formation of inactive aggregates in free IFN or to differences between the quantitative methods (amino acid analysis for PEG-IFN samples and RP-HPLC for IFN- β).

TABLE 3 Daudi antiproliferation test

	IC50Dosage form*	Fold increase for IFN
			IFN- β (plate 1)	1153.1	-
PEG[30kD]-IFN(71A)	695.6	1.6X
			IFN- β (plate 2)	1005.8	-
PEG[40kD]-IFN(71B)	629.4	1.7X

^*pg/ml

Example 4: pharmacokinetic study of intravenous drug administration in mice

Mice were injected with 100ng of IFN- β [30kD ] -IFN- β or PEG [ 2x 20kD ] -IFN- β, after which blood was taken at the indicated times, IFN- β 1 specific ELIAS (Toray industries) was used to determine the serum concentration of IFN- β and the results are shown in FIG. 8. 28 female B6D2F1 mice (6-8 weeks) (approximately 20 g each) were divided into 4 groups, group 1 containing 9 mice that were bolus injected with 200 microliters of 500ng/ml human IFN- β (final dose of 100 ng/mouse), group 2(9 mice) received 200 microliters of PEG 30-kD-IFN- β, group 3 received 200 microliters of equal PEG (2 x 20kD) -IFN- β; group 4 is 3 non-coagulated injected mice as a negative control, group 9 mice were treated with capillary collection (approximately 200 kD/L) -IFN- β or PEG-539 blood samples, and all IFN-20 kD samples were stored at room temperature for a significant time following the IFN-20 ℃ IFN-20 kD interval and the IFN-20 kD curve was determined by centrifugation of the IFN-20 kD IFN-20-IFN-7 IFN-20-hr blood samples.

Subcutaneous administration of drugs

The mice were injected subcutaneously with IFN- β and PEG-IFN (100 ng/mouse). figure 9 shows that the area under the total curve (AUC) of the PEG-IFN sample was significantly increased compared to free IFN- β. pharmacokinetic studies were consistent with PEG-IFN samples having longer half-lives and increased area under the curve.

Example 5: conjugation of Low molecular weight PEG molecules to Polypeptides

IFN- β and OPSS-PEG_2K-hydrazide linkage

Recombinant human IFN- β was dissolved in 50mM sodium acetate buffer, pH3.8 at 0.33mg/ml approximately 3.6mg (40 moles more than protein moles) of a heterobifunctional PEG reagent, OPSS-PEG_2KHydrazide (dissolved in 2ml deionized water) was added to 3ml of 0.33mg/ml (0.99mg) IFN- β, both were allowed to react at 45 ℃ for 1 hour in a polypropylene tube and the reaction mixture was analyzed by capillary electrophoresis to determine the degree of modification. the yield typically varied from 90-97% depending on the purity of IFN- β and PEG reagents the solution was then applied to a size exclusion chromatography column (Superdex 75, Pharmacia), eluted with 5mM sodium phosphate, 150mM naci, ph7.0 buffer, the peaks collected and the single pegylated IFN- β fractions pooled together by SDS-PAGE analysis and then used in the further modification step with high molecular weight PEG.

IFN- β sum (OPSS) ₂ -PEG ₃₄₀₀ Connection of

Recombinant human IFN- β was dissolved in 50mM sodium acetate buffer, pH3.8 at 0.33mg/ml approximately 6.1mg (40 moles more than protein) homobifunctional PEG reagent, (OPSS)₂-PEG₃₄₀₀(solution)In 2ml of deionized water) to 3ml of 0.33mg/ml (0.99mg) IFN- β, which were reacted in a polypropylene tube at 50 ℃ for 2 hours, the reaction was monitored by nondegradable SDS-PAGE and the final reaction mixture was analyzed by capillary electrophoresis to determine the degree of modification, and IFN- β, which is typically more than 95% modified.

Example 6: conjugation of a second PEG molecule to a Low molecular weight PEGylated polypeptide

With mPEG_30kAcetaldehyde (ALD) vs. IFN-S-S-PEG_2kModification of hydrazides

Will be 20 moles more mPEG than protein_30kALD to IFN-S-S-PEG in example 5_2kHydrazide in combined components. The reaction was allowed to proceed at room temperature (25 ℃) for 4 hours and the amount of modification was determined by applying the sample to a size exclusion chromatography column (Superose 6, Pharmacia). The amount of modification in this reaction depends on the PEG reagent and the reaction conditions, and is typically greater than 80%.

Having now fully described this invention, it is to be understood that one of ordinary skill in the art can, without undue experimentation, practice the same within a wide range of equivalent parameters, concentrations, and conditions without departing from the spirit and scope of the invention.

While the invention has been described in conjunction with specific embodiments thereof, it will be understood that other modifications may be made. This application is intended to cover any variations, uses, or adaptations of the invention following, in general, the principles of the invention and including such departures from the present disclosure as come within known or customary practice within the art to which the invention pertains and as may be applied to the essential features hereinbefore set forth as follows in the scope of the appended claims.

All references cited herein, including journal articles or abstracts, published or unpublished U.S. or foreign patent applications, issued U.S. or foreign patents, or any other references, are incorporated by reference herein in their entirety, including the data, tables, figures, and text in all cited references, and additionally, all references cited herein are also incorporated by reference in their entirety.

Reference to known method steps, conventional method steps, known methods, or conventional methods is not an admission in any aspect that any aspect, description, or embodiment of the present invention is disclosed, taught, or suggested in the relevant art.

The foregoing description of the specific embodiments will so fully reveal the general nature of the invention that others can, by applying knowledge within the skill of the art (including the contents of the references cited herein), readily modify and/or adapt for various applications such specific embodiments, without undue experimentation, without departing from the general concept of the present invention. Therefore, such changes and modifications are to be considered within the meaning and range of equivalents of the disclosed embodiments, based on the teaching and guidance presented herein. It is also to be understood that the phraseology or terminology herein is for the purpose of description and not of limitation, such that the terminology or phraseology of the present specification is to be interpreted by the skilled artisan in light of the teachings and guidance presented herein, in combination with the knowledge of one of ordinary skill in the art.

Claims (9)

1. A polyol-interferon- β conjugate, wherein the conjugate has a Cys that binds to human interferon- β¹⁷Covalently bound polyalkylene glycol molecules.

2. The polyol-interferon- β conjugate of claim 1, wherein the polyalkylene glycol molecule is a polyethylene glycol molecule.

3. A method of producing the polyol-interferon- β conjugate of claim 1, the process comprising the steps of:

reacting a thiol-reactive polyol agent with interferon- β to site-specifically covalently bind a polyalkylene glycol molecule to human interferon- β to produce a polyol-interferon- β conjugate, and

recovering the resulting polyol-interferon- β conjugate;

the thiol-reactive polyol agent is a polyol derivative having a functional group selected from the group consisting of a dithio-p-pyridine, a vinyl sulfone, a maleimide, and an iodoacetamide.

4. The method of claim 3, wherein the thiol-reactive polyol is a thiol-reactive PEGylating agent.

5. The method of claim 3 or claim 4, wherein the thiol-reactive polyol agent is monomethoxylated.

6. The method of claim 3 or claim 4, wherein the thiol-reactive polyol agent is bifunctional.

7. The method of claim 3 or claim 4, wherein the thiol-reactive polyol agent is a dithio-p-pyridine derivative of a monomethoxylated polyol.

8. The method of claim 3, wherein the reacting step is carried out at an acidic pH at which interferon- β is stable.

9. A pharmaceutical composition comprising as an active ingredient the polyol-interferon- β conjugate of claim 1, and a pharmaceutically acceptable carrier, excipient or adjuvant.